Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 880881107 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
| BlackRock, Inc. 13G/A | 6.8% |
2/5/2025
Event 12/31/2024
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (10) | ||||
| Schonfeld Strategic Advisors LLC 13G/A | 4.9% |
5/15/2025
Event 3/31/2025
|
||
|
Orbimed Advisors LLC
13D/A
|
4.8% |
11/5/2025
Event 11/3/2025
|
||
| Orbimed Advisors LLC | 4.8% | |||
| Orbimed Capital GP VII LLC | 3.1% | |||
| OrbiMed Asia GP III, L.P. | 1.2% | |||
| OrbiMed Advisors III Ltd | 1.2% | |||
| OrbiMed Genesis GP LLC | 0.5% | |||
|
Citadel Advisors LLC
13G/A
|
4.1% |
2/14/2025
Event 12/31/2024
|
||
| Citadel Advisors LLC | 3.9% | |||
| Citadel Advisors Holdings LP | 3.9% | |||
| Citadel GP LLC | 3.9% | |||
| Citadel Securities LLC | 0.2% | |||
| Citadel Securities Group LP | 0.2% | |||
| Citadel Securities GP LLC | 0.2% | |||
| Kenneth Griffin | 4.1% | |||
|
Deep Track Capital, LP
13G/A
|
3.0% |
2/13/2026
Event 12/31/2025
|
||
| Deep Track Capital, LP | 3.0% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 3.0% | |||
| David Kroin | 3.0% | |||
|
Vivo Opportunity Fund Holdings, L.P.
13G/A
|
2.5% |
2/13/2026
Event 1/31/2025
|
||
| Vivo Capital Fund VIII, L.P. | 0.9% | |||
| Vivo Capital Surplus Fund VIII, L.P. | 0.1% | |||
| Vivo Capital VIII, LLC | 1.0% | |||
| Vivo Opportunity Fund Holdings, L.P. | 2.5% | |||
| Vivo Opportunity, LLC | 2.5% | |||
| Vivo Opportunity Cayman Fund, L.P. | 0.2% | |||
| Vivo Opportunity Cayman, LLC | 0.2% | |||
|
Adage Capital Management, L.P.
13G/A
|
1.8% |
5/13/2026
Event 3/31/2026
|
||
| Adage Capital Management, L.P. | 1.8% | |||
| Robert Atchinson | 1.8% | |||
| Phillip Gross | 1.8% | |||
|
Commodore Capital LP
13G/A
|
1.4% |
2/17/2026
Event 12/31/2025
|
||
| Commodore Capital LP | 1.4% | |||
| Commodore Capital Master LP | 1.4% | |||
| Robert Egen Atkinson | 1.4% | |||
| Michael Kramarz | 1.4% | |||
|
Soleus Capital Master Fund, L.P.
13G/A
|
0.2% |
2/12/2026
Event 12/31/2025
|
||
| Soleus Capital Master Fund, L.P. | 0.2% | |||
| Soleus Capital, LLC | 0.2% | |||
| Soleus Capital Group, LLC | 0.2% | |||
| Soleus Capital Management, L.P. | 0.2% | |||
| Soleus GP, LLC | 0.2% | |||
| Guy Levy | 0.2% | |||
| Morgan Stanley 13G/A | 0% |
6/5/2026
Event 5/31/2026
|
||
| Vanguard Group Inc 13G/A | 0% |
3/27/2026
Event 3/13/2026
|
||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q2 | 2 | 12.5 k | $660 k |
| 2026 Q1 | 361 | 125 M | $6.56 B |
| 2025 Q4 | 259 | 123 M | $4.95 B |
| 2025 Q3 | 151 | 89.3 M | $671 M |
| 2025 Q2 | 136 | 83.3 M | $311 M |
| 2025 Q1 | 146 | 83.1 M | $230 M |
| 2024 Q4 | 165 | 88.1 M | $488 M |
| 2024 Q3 | 170 | 79.6 M | $663 M |
| 2024 Q2 | 136 | 66.1 M | $450 M |
| 2024 Q1 | 122 | 64.8 M | $425 M |
| 2023 Q4 | 114 | 65.6 M | $426 M |
| 2023 Q3 | 101 | 61.7 M | $310 M |
| 2023 Q2 | 113 | 57.7 M | $505 M |
| 2023 Q1 | 80 | 53.2 M | $630 M |
| 2022 Q4 | 67 | 49.8 M | $507 M |
| 2022 Q3 | 46 | 30.3 M | $178 M |
| 2022 Q2 | 43 | 14.7 M | $36.6 M |
| 2022 Q1 | 45 | 16.8 M | $50.0 M |
| 2021 Q4 | 38 | 16.5 M | $117 M |
| 2021 Q3 | 35 | 16.7 M | $174 M |
| 2021 Q2 | 37 | 16.6 M | $204 M |
| 2021 Q1 | 43 | 17.9 M | $394 M |